JPWO2022221696A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022221696A5 JPWO2022221696A5 JP2023563189A JP2023563189A JPWO2022221696A5 JP WO2022221696 A5 JPWO2022221696 A5 JP WO2022221696A5 JP 2023563189 A JP2023563189 A JP 2023563189A JP 2023563189 A JP2023563189 A JP 2023563189A JP WO2022221696 A5 JPWO2022221696 A5 JP WO2022221696A5
- Authority
- JP
- Japan
- Prior art keywords
- cell
- dna
- item
- composition
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163176225P | 2021-04-17 | 2021-04-17 | |
| US63/176,225 | 2021-04-17 | ||
| PCT/US2022/025075 WO2022221696A1 (en) | 2021-04-17 | 2022-04-15 | Inhibitors of dna-dependent protein kinase and compositions and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024516376A JP2024516376A (ja) | 2024-04-15 |
| JPWO2022221696A5 true JPWO2022221696A5 (https=) | 2025-04-22 |
| JP2024516376A5 JP2024516376A5 (https=) | 2025-04-22 |
Family
ID=81581217
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023563189A Pending JP2024516376A (ja) | 2021-04-17 | 2022-04-15 | Ｄｎａ依存性プロテインキナーゼの阻害剤ならびにその組成物及び使用 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20240300977A1 (https=) |
| EP (1) | EP4323360A1 (https=) |
| JP (1) | JP2024516376A (https=) |
| KR (1) | KR20240017791A (https=) |
| CN (1) | CN117940426A (https=) |
| AU (1) | AU2022258733A1 (https=) |
| BR (1) | BR112023021429A2 (https=) |
| CA (1) | CA3216875A1 (https=) |
| CL (1) | CL2023003079A1 (https=) |
| CO (1) | CO2023015478A2 (https=) |
| CR (1) | CR20230535A (https=) |
| IL (1) | IL307740A (https=) |
| MX (1) | MX2023012236A (https=) |
| TW (1) | TW202309034A (https=) |
| WO (1) | WO2022221696A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SMT202500271T1 (it) | 2020-07-02 | 2025-09-12 | Incyte Corp | Composti di urea triciclici come inibitori di v617f di jak2 |
| US20250305004A1 (en) * | 2022-05-13 | 2025-10-02 | The Board Of Trustees Of The Leland Stanford Junior University | Enhancing gene targeting efficiency in human cells with dna-pk inhibitor treatment |
| TW202440086A (zh) * | 2023-03-13 | 2024-10-16 | 美商英塞特公司 | 作為激酶抑制劑之雙環脲 |
| TW202515994A (zh) | 2023-08-14 | 2025-04-16 | 美商英特利亞醫療公司 | 用於對ｃｄ７０進行基因修飾之組合物及方法 |
| WO2025049481A1 (en) * | 2023-08-28 | 2025-03-06 | Intellia Therapeutics, Inc. | Methods of editing an hla-a gene in vitro |
| WO2025049432A1 (en) | 2023-08-28 | 2025-03-06 | Intellia Therapeutics, Inc. | Methods for editing hla-a in cells pre-screened for the absence of one or both alleles of hla-h*01 |
| WO2025128871A2 (en) | 2023-12-13 | 2025-06-19 | Renagade Therapeutics Management Inc. | Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents |
| WO2025137301A1 (en) | 2023-12-20 | 2025-06-26 | Intellia Therapeutics, Inc. | Methods for rapid engineering of cells |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030083272A1 (en) | 1997-09-19 | 2003-05-01 | Lahive & Cockfield, Llp | Sense mrna therapy |
| GB0119865D0 (en) | 2001-08-14 | 2001-10-10 | Cancer Res Campaign Tech | DNA-PK inhibitors |
| WO2006007712A1 (en) | 2004-07-19 | 2006-01-26 | Protiva Biotherapeutics, Inc. | Methods comprising polyethylene glycol-lipid conjugates for delivery of therapeutic agents |
| WO2011076807A2 (en) | 2009-12-23 | 2011-06-30 | Novartis Ag | Lipids, lipid compositions, and methods of using them |
| WO2011091324A2 (en) | 2010-01-22 | 2011-07-28 | The Scripps Research Institute | Methods of generating zinc finger nucleases having altered activity |
| CN103668470B (zh) | 2012-09-12 | 2015-07-29 | 上海斯丹赛生物技术有限公司 | 一种dna文库及构建转录激活子样效应因子核酸酶质粒的方法 |
| DK2931898T3 (en) | 2012-12-12 | 2016-06-20 | Massachusetts Inst Technology | CONSTRUCTION AND OPTIMIZATION OF SYSTEMS, PROCEDURES AND COMPOSITIONS FOR SEQUENCE MANIPULATION WITH FUNCTIONAL DOMAINS |
| WO2014093694A1 (en) | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Crispr-cas nickase systems, methods and compositions for sequence manipulation in eukaryotes |
| CA2895155C (en) | 2012-12-17 | 2021-07-06 | President And Fellows Of Harvard College | Rna-guided human genome engineering |
| EP3608308B1 (en) | 2013-03-08 | 2021-07-21 | Novartis AG | Lipids and lipid compositions for the delivery of active agents |
| SI3527563T1 (sl) | 2013-03-12 | 2022-01-31 | Vertex Pharmaceuticals Incorporated | Inhibitorji DNA-PK |
| DE102013008118A1 (de) | 2013-05-11 | 2014-11-13 | Merck Patent Gmbh | Arylchinazoline |
| US20150165054A1 (en) | 2013-12-12 | 2015-06-18 | President And Fellows Of Harvard College | Methods for correcting caspase-9 point mutations |
| ES2895651T3 (es) | 2013-12-19 | 2022-02-22 | Novartis Ag | Lípidos y composiciones lipídicas para la administración de agentes activos |
| EP3169309B1 (en) | 2014-07-16 | 2023-05-10 | Novartis AG | Method of encapsulating a nucleic acid in a lipid nanoparticle host |
| EP4286012A3 (en) | 2015-09-17 | 2024-05-29 | ModernaTX, Inc. | Compounds and compositions for intracellular delivery of therapeutic agents |
| TWI773666B (zh) | 2016-03-30 | 2022-08-11 | 美商英特利亞醫療公司 | Crispr/cas 組分之脂質奈米粒子調配物 |
| WO2018073393A2 (en) | 2016-10-19 | 2018-04-26 | Cellectis | Tal-effector nuclease (talen) -modified allogenic cells suitable for therapy |
| SMT202100225T1 (it) | 2016-12-20 | 2021-05-07 | Astrazeneca Ab | Composti di ammino-triazolopiridina e loro uso nel trattamento del cancro |
| PT3688162T (pt) | 2017-09-29 | 2024-04-23 | Intellia Therapeutics Inc | Formulações |
| WO2019147805A2 (en) | 2018-01-26 | 2019-08-01 | The Board Of Trustees Of The Leland Stanford Junior University | Regulatory t cells targeted with chimeric antigen receptors |
| WO2020072605A1 (en) | 2018-10-02 | 2020-04-09 | Intellia Therapeutics, Inc. | Ionizable amine lipids |
| IL314386A (en) | 2018-12-05 | 2024-09-01 | Intellia Therapeutics Inc | amine modified lipids |
| WO2020219876A1 (en) | 2019-04-25 | 2020-10-29 | Intellia Therapeutics, Inc. | Ionizable amine lipids and lipid nanoparticles |
| WO2020257325A1 (en) * | 2019-06-17 | 2020-12-24 | Vertex Pharmaceuticals Inc. | Compositions and methods for editing beta-globin for treatment of hemaglobinopathies |
-
2022
- 2022-04-15 CR CR20230535A patent/CR20230535A/es unknown
- 2022-04-15 IL IL307740A patent/IL307740A/en unknown
- 2022-04-15 BR BR112023021429A patent/BR112023021429A2/pt not_active Application Discontinuation
- 2022-04-15 TW TW111114469A patent/TW202309034A/zh unknown
- 2022-04-15 KR KR1020237039428A patent/KR20240017791A/ko active Pending
- 2022-04-15 JP JP2023563189A patent/JP2024516376A/ja active Pending
- 2022-04-15 MX MX2023012236A patent/MX2023012236A/es unknown
- 2022-04-15 EP EP22721588.6A patent/EP4323360A1/en active Pending
- 2022-04-15 WO PCT/US2022/025075 patent/WO2022221696A1/en not_active Ceased
- 2022-04-15 CN CN202280042815.9A patent/CN117940426A/zh active Pending
- 2022-04-15 AU AU2022258733A patent/AU2022258733A1/en active Pending
- 2022-04-15 CA CA3216875A patent/CA3216875A1/en active Pending
- 2022-04-15 US US18/287,227 patent/US20240300977A1/en active Pending
-
2023
- 2023-10-16 CL CL2023003079A patent/CL2023003079A1/es unknown
- 2023-11-16 CO CONC2023/0015478A patent/CO2023015478A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12559536B2 (en) | CD33 specific chimeric antigen receptors | |
| US12344651B2 (en) | CD19 and CD22 chimeric antigen receptors and uses thereof | |
| JP7565271B2 (ja) | ガンマ－デルタｔ細胞およびナチュラルキラー細胞の治療的調製物ならびに製造および使用する方法 | |
| Diorio et al. | Allogeneic chimeric antigen receptor cell therapies for cancer: progress made and remaining roadblocks | |
| JP7292213B2 (ja) | Ｃｒｉｓｐｒ／ｃｐｆ１を用いる、ｔ細胞における遺伝子編集のための組成物および方法 | |
| JP7471289B2 (ja) | 抗ｌｉｖ１免疫細胞癌療法 | |
| US20210380944A1 (en) | Therapeutic preparations of gamma-delta t cells and natural killer cells and methods for making and using them | |
| EP3914270A1 (en) | Compositions and methods for targeting mutant ras | |
| KR20210045985A (ko) | 항-bcma 키메라 항원 수용체의 용도 | |
| JP2023547695A (ja) | 増強された免疫療法のためのシステムおよび方法 | |
| US20110020308A1 (en) | Expression of transgenic t cell receptors in lak-t cells | |
| CN114921417B (zh) | 双基因定点整合通用型car-t细胞的制备方法及其应用 | |
| TW202325320A (zh) | 用於產生原代免疫細胞之方法 | |
| JPWO2022221696A5 (https=) | ||
| US20220202900A1 (en) | Compositions and methods for crispr/cas9 knock-out of cd33 in human hematopoietic stem / progenitor cells for allogenic transplantation in patients with relapsed - refractory acute myeloid leukemia | |
| EP4370676A2 (en) | Compositions and methods for targeting, editing or modifying human genes | |
| US20250290040A1 (en) | Gamma delta t cell compositions and methods of use | |
| JP2021522865A (ja) | 栄養要求性調節可能な細胞を使用する遺伝子療法の方法および組成物 | |
| WO2020179931A1 (ja) | ハイスループット遺伝子編集技術 | |
| WO2025137468A1 (en) | Cell therapies for type 1 diabetes | |
| WO2025207642A1 (en) | Cxcr3 isoforms to improve recombinant receptor trafficking | |
| HK40082080A (en) | Compositions and methods for delivery of nucleic acids to cells | |
| WO2021231954A1 (en) | Methods for immunotherapy | |
| HK40062145B (zh) | 由液体肿瘤扩增肿瘤浸润淋巴细胞及其治疗用途 | |
| JPWO2022182763A5 (https=) |